EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Oligoprogressive renal cell carcinoma: What is the role of surgery?

Chiara Re, William H J Ince, Leo Bickley, James P Blackmur, Mouhamad H Ismail, Justicia Kyeremeh, Teele Kuusk iD, Eva Mendes Serrao, James O Jones, Grant D Stewart iD

BJU International · 2026-08 · 138 (2) · 219-228

DOI: 10.1111/bju.70281 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BJU International, online erschienen am 13.04.2026. Verfasst von Chiara Re und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Cambridge, Cambridge Biomedical Centre, Cambridge, UK. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Nephrectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research (NIHR), Department of Health and Social Care, Cancer Research UK Cambridge Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications.

Methods

A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and original studies. Additional sources were identified through manual reference screening.

Results

Oligoprogression in RCC likely arises from clonal evolution dynamics, with spatially confined subclone mutations and microenvironmental niches yielding differential responses to treatment. Complete metastasectomy may offer a survival benefit, spare patients toxic side effects of systemic therapy, and offers the possibility of histopathological and molecular characterisation of residual disease. Surgery is also particularly important in delayed cytoreductive nephrectomy as the site of oligoprogression. However, this must be weighed against non‐negligible surgical morbidity and complication rates. International guidelines recognise the role of surgical resection in the metastatic setting but emphasise low evidence levels and careful patient selection requirements.

Conclusion

Limited evidence derived from the oligometastatic context constrains optimal patient selection and timing strategies in oligoprogressive RCC. Following the establishment of consensus over definitions and research gaps, future research integrating molecular biomarkers, novel imaging tracers, and multicentre collaborative studies will be essential to develop evidence‐based surgical management protocols for this increasingly common clinical scenario.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsNephrectomyHumansDisease Progression

Stichwörter der Autor:innen

local treatmentmetastasis‐directed therapymetastatic kidney canceroligoprogressionoligorecurrencerenal cell carcinoma

Autor:innen und Institutionen

  • Department of Surgery, University of Cambridge, Cambridge Biomedical Centre, Cambridge, UK.
  • CRUK Cambridge Centre, University of Cambridge, Cambridge, UK.
  • IRCCS San Raffaele Scientific Institute, Division of Experimental Oncology/Unit of Urology, Urological Research Institute (URI), Milan, Italy.
  • Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Department of Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Department of Urology, Western General Hospital, Edinburgh, UK.

ORCID-Profile: Teele Kuusk, Grant D Stewart

Förderung

  • National Institute for Health Research (NIHR)
  • Department of Health and Social Care
  • Cancer Research UK Cambridge Centre
  • NIHR Cambridge Biomedical Research Centre

Zitieren

APA

Re, C., Ince, W. H. J., Bickley, L., Blackmur, J. P., Ismail, M. H., Kyeremeh, J., Kuusk, T., Serrao, E. M., Jones, J. O., & Stewart, G. D. (2026). Oligoprogressive renal cell carcinoma: What is the role of surgery?. BJU International, 138(2), 219-228. https://doi.org/10.1111/bju.70281

Vancouver

Re C, Ince WHJ, Bickley L, Blackmur JP, Ismail MH, Kyeremeh J, et al. Oligoprogressive renal cell carcinoma: What is the role of surgery?. BJU International. 2026;138(2):219-228. doi:10.1111/bju.70281

BibTeX
@article{Re2026,
  author = {Re, Chiara and Ince, William H J and Bickley, Leo and Blackmur, James P and Ismail, Mouhamad H and Kyeremeh, Justicia and Kuusk, Teele and Serrao, Eva Mendes and Jones, James O and Stewart, Grant D},
  title = {Oligoprogressive renal cell carcinoma: What is the role of surgery?},
  journal = {BJU International},
  year = {2026},
  volume = {138},
  number = {2},
  pages = {219--228},
  doi = {10.1111/bju.70281}
}
Kostenlos starten →